Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:37 12/06/2024 am IST			5-day change	1st Jan Change
0.4 ^AUD	-6.98%		-11.11%	+15.94%

05/06	Immutep Completes Stock Offering	MT
03/06	Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	MT

Frédéric Triebel Joins Prima Biomed Ltd as its New Chief Scientific Officer and Chief Medical Officer

December 17, 2014 at 06:53 pm IST

Prima BioMed Ltd. announced acquisition of Immutep SA has been completed. Prima also announced that Professor Frédéric Triebel has joined the company as its new Chief Scientific Officer and Chief Medical Officer. Professor Triebel originally developed Immutep's LAG-3 technology and was its founder and Scientific and Medical Director.

Latest news about Immutep Limited

Immutep Completes Stock Offering	06/06	MT
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	03/06	MT
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	03/06	MT
Immutep Raising AU$100 Million for Phase Three Trial	03/06	MT
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	03/06	CI
Capital One Initiates Immutep at Overweight Rating With $10 Price Target	17/05	MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15/05	MT
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15/05	CI
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	03/05	CI
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02/05	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	30/04	CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	30/04	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25/04	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	25/04	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24/04	CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18/04	CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18/04	MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17/04	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17/04	MT
Encouraging results for Immutep's cancer therapies	25/03	FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	05/03	CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	28/02	MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI

Chart Immutep Limited

Duration

Period

More charts

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4 AUD

Average target price

0.944 AUD

Spread / Average Target

+136.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUTEP LIMITED	+15.94%	337M
MODERNA, INC.	+50.13%	56.87B
LONZA GROUP AG	+37.15%	39.72B
IQVIA HOLDINGS INC.	-5.93%	39.27B
CELLTRION, INC.	-6.90%	28.73B
ICON PUBLIC LIMITED COMPANY	+13.04%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-15.90%	19.79B
MEDPACE HOLDINGS, INC.	+31.22%	12.28B
UNITED THERAPEUTICS CORPORATION	+27.69%	12.23B
BIO-TECHNE CORPORATION	+0.24%	12.12B

Other Biotechnology & Medical Research